Symbiotec PharmaSymbiotec Pharma

Financials

Symbiotec has established a global presence over more than one decade of experience by partnering with other leading global pharmaceutical companies by offering high quality products at competitive price. Symbiotec with its next phase of investment in backward integration and enhancement in manufacturing capabilities is rightly poised to expand its reach in regulated markets in order to emerge as a dominant global player in the Cortico- Steroids and Hormone segment.

Its robust financial health is re-affirmed by the Credit rating “A- ” by CARE one of India’s leading rating agency, which is a clear indicator of its Value delivery over the years.

ROCE*

2009-2010

2010-2011

2015-16

2011-2012

2012-2013

2014-2015

2013-2014

 *Based on net debts

** ROCE is lower due to Higher Investments.

Symbiotec’s sales growth over last five years has been remarkable. The Company is able to almost triple its sales over last 5 years. Net worth of the Company has also shown significant improvement in last couple of years. Steady growth in sales and net worth backed up by positive ROCE trend is reflective of its strength in its quality and processes and rigour in financial discipline which is comparable with any other global player in the same space.

SALES CHART (IN MN USD)

(2015-2016): 62Mn USD
(2014-2015): 62Mn USD
(2013-2014) : 52Mn USD
(2012-2013) : 42Mn USD
(2011-2012) : 30Mn USD
(2010-2011) : 27Mn USD

NET WORTH (IN MN USD)

(2015-2016): 40.93Mn USD
(2014-2015): 39.03Mn USD
(2013-2014): 35.59Mn USD
(2012-2013): 17.88Mn USD
(2011-2012): 8.87Mn USD
(2010-2011): 9.42Mn USD

CAGR % (REVENUE)

(2015-2016) : 27%
(2014-2015) : 32%
2013-2014) : 30%
2012-2013) : 31%
2011-2012) : 30%
2010-2011) : 31%

Financials of Subsidiaries

FY 2015-16

NaviSci Pte. Ltd.

Notice of AGM

2017

FY 2015-16

SPL Lifescience India Pvt. Ltd.

HAVE A QUERY ? WE ARE HERE TO HELP